These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19297547)

  • 1. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
    Donahue RN; McLaughlin PJ; Zagon IS
    Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis.
    Klocek MS; Sassani JW; Donahue RN; McLaughlin PJ; Zagon IS
    Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5054-61. PubMed ID: 20463323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
    Zagon IS; Donahue RN; McLaughlin PJ
    Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1154-61. PubMed ID: 19675283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation.
    Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
    Mol Biol Cell; 2009 Jan; 20(1):319-27. PubMed ID: 18923142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.
    Avella DM; Kimchi ET; Donahue RN; Tagaram HR; McLaughlin PJ; Zagon IS; Staveley-O'Carroll KF
    Am J Physiol Regul Integr Comp Physiol; 2010 Feb; 298(2):R459-66. PubMed ID: 19923357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer.
    Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
    Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
    Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
    Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
    McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
    BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
    Zagon IS; Porterfield NK; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 Jun; 238(6):589-99. PubMed ID: 23918871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
    Zagon IS; Donahue R; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
    Campbell AM; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2013 Jan; 90():43-51. PubMed ID: 22985690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
    Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
    Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
    Kren NP; Zagon IS; McLaughlin PJ
    Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation.
    Cheng F; McLaughlin PJ; Banks WA; Zagon IS
    Am J Physiol Regul Integr Comp Physiol; 2010 Sep; 299(3):R774-85. PubMed ID: 20592180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2012 Feb; 237(2):167-77. PubMed ID: 22328595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
    Qu N; Wang X; Meng Y; Shan F
    Int Immunopharmacol; 2019 Oct; 75():105723. PubMed ID: 31408839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.